<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04615325</url>
  </required_header>
  <id_info>
    <org_study_id>GR42163</org_study_id>
    <nct_id>NCT04615325</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Participants With Geographic Atrophy</brief_title>
  <official_title>A Phase 1a, Multicenter, Open Label, Single Dose, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of RO7303359 in Patients With Geographic Atrophy Secondary to Age Related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multicenter study will investigate the safety, tolerability, pharmacokinetics, and&#xD;
      immunogenicity of RO7303359 following single Intravitreal (ITV) injection in participants&#xD;
      with geographic atrophy (GA) secondary to age related macular degeneration (AMD). The&#xD;
      participants will receive ITV injections of RO7303359 in the single ascending dose stage and&#xD;
      maximum tolerated dose (MTD) or maximum tested dose (MTeD) of RO7303359 will be administered&#xD;
      in the expansion stage.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 8, 2020</start_date>
  <completion_date type="Anticipated">February 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 22, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants with Adverse Events and Serious Adverse Events</measure>
    <time_frame>Up to 12 Weeks</time_frame>
    <description>Adverse events will be determined by the World Health Organization toxicity grading scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with changes in best corrected visual acuity (BCVA) following RO7303359 administration</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of RO7303359</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aqueous humor concentration of RO7303359</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of serum anti drug antibodies (ADAs) at baseline and incidence of serum ADAs</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with anti-drug-antibodies (ADA) to RO7303359</measure>
    <time_frame>Up to 12 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">63</enrollment>
  <condition>Geographic Atrophy</condition>
  <arm_group>
    <arm_group_label>Single ascending dose stage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a single dose of RO7303359, in multiple escalating cohorts (A-D)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion cohort stage</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the maximum tolerated dose (MTD) or the maximum tested dose (MTeD) as determined in the single ascending dose stage.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optional cohort E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An optional additional cohort maybe added with the dose not exceed the MTD or MTeD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optional cohort F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An optional additional cohort maybe added with the dose not exceed the MTD or MTeD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7303359</intervention_name>
    <description>RO730359 will be administered at a single intravitreal injection</description>
    <arm_group_label>Expansion cohort stage</arm_group_label>
    <arm_group_label>Optional cohort E</arm_group_label>
    <arm_group_label>Optional cohort F</arm_group_label>
    <arm_group_label>Single ascending dose stage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Ocular Inclusion Criteria Study Eye:&#xD;
&#xD;
          -  Well-demarcated area of GA secondary to AMD in the absence of choroidal&#xD;
             neovascularization (CNV)&#xD;
&#xD;
          -  GA area must be &gt;= 0.5 disc area (1.25 mm2)&#xD;
&#xD;
        Ocular Exclusion Criteria, Study eye:&#xD;
&#xD;
          -  GA due to causes other than AMD&#xD;
&#xD;
          -  History of vitrectomy surgery, submacular surgery, or other surgical intervention for&#xD;
             AMD&#xD;
&#xD;
          -  Previous laser photocoagulation for CNV, diabetic macular edema, retinal vein&#xD;
             occlusion, or proliferative diabetic retinopathy&#xD;
&#xD;
          -  Prior treatment with Visudyne, external beam radiation therapy (for intraocular&#xD;
             conditions), or transpupillary thermotherapy&#xD;
&#xD;
        Ocular Exclusion Criteria, Both eyes:&#xD;
&#xD;
          -  Evidence of prior or active CNV&#xD;
&#xD;
          -  Previous participation in interventional clinical trials for GA or dry AMD, except for&#xD;
             vitamins and minerals, irrespective of the route of administration (i.e. ocular or&#xD;
             systemic) within the last 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: GR42163 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Retina Partners</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northern California Retina Vitreous Associates</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants Med Group</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>California Retina Consultants - Santa Maria</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Colorado Retina Associates, PC</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Eye Associates</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Associates of Florida</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33711-1141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Retina and Macula Associates, PC</name>
      <address>
        <city>Oak Forest</city>
        <state>Illinois</state>
        <zip>60452</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Associated Retinal Consultants PC</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sierra Eye Associates</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Western Carolina Retinal Associate PA</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Retina PC.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Research Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78750</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Foundation of the Southwest</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 29, 2020</study_first_submitted>
  <study_first_submitted_qc>October 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 4, 2020</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Geographic Atrophy</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

